LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates
December 17, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
LogicBio Reports Third Quarter 2019 Financial Results and Provides Business Updates
November 12, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
LogicBio Therapeutics to Present at November Conferences
November 07, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
LogicBio Therapeutics to Present New Data on Next Generation Capsid Development Program and GeneRide™ Platform Program at the European Society of Gene and Cell Therapy 27th Annual Congress
October 16, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Oct. 16, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
LogicBio Therapeutics to Present at October Conferences
September 26, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
LogicBio Reports Second Quarter 2019 Financial Results and Provides Business Updates
August 13, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
LogicBio Therapeutics Receives Rare Pediatric Disease Designation for LB-001 for the Treatment of Methylmalonic Acidemia
July 16, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
LogicBio Secures Up To $20 Million Debt Facility with Oxford Finance LLC and Horizon Technology Finance
July 02, 2019 16:05 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
LogicBio to Present at the Jefferies 2019 Healthcare Conference
May 30, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced...
LogicBio Reports First Quarter 2019 Financial Results and Provides Business Updates
May 14, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare...